The initial wave of BsAbs recognize CD3 on the T-cells whereas the MM specific surface markers that have been targeted include BCMA, GPRC5D, CD38, FCRH5 (Table 1). Although there are BsAbs in preclinical development exploring CD16 in place of CD3 to help direct natural killer cells ...
et al. Defining an optimal dual-targeted CAR T-cell therapy approach simultaneously targeting BCMA and GPRC5D to prevent BCMA escape-driven relapse in multiple myeloma. Blood Cancer Discov. 1, 146–154 (2020). Article Google Scholar Garfall, A. L. & June, C. H. Trispecific antibodies ...
GPRC5D等新兴靶点崭露头角 28 29 数据来源:Bispecifics,trispecifics,and other novel immune treatments in myeloma,西南证券整理 CA 72、R-T细胞 双特异性抗体 ADCs 优势 极强的应答率,包括重度预处理患者的 MRD 阴性率 现货 现货 一次性干预;长期化疗,中位生存期约为 1 年 应答强 有效的响应率 老年患者...
此外,最近一项多发性骨髓瘤小 ORR 达 60%;Talquetamab( 首个 GPRC5D/CD3 双 鼠异种移植模型(包括 BCMA 表达缺乏模型)中, 抗)在 MonumenTAL-1 研究中对于既往接受过 T 细以 FcRH5 为靶点的 CAR-T 也表现出强大的肿瘤特 胞重定向治疗的 RRMM 患者 ORR 分别为 72.9% 和 异性反应 [19],有望成为极具...
Dual-targeted CAR-T cell constructs are also in development, and a combination of BCMA and GPRC5D showed promising activity in preclinical models [102]. Talquetamab is a first-in-class humanized DuoBody® with an IgG4 backbone that binds to GPRC5D and CD3 to redirect T-cells to myeloma...